Objective To investigate effects of electroacupuncture （EA） on expression of intercellular adhesion molecule-1 （ICAM-1） in the rat of local cerebral ischemia-reperfusion. Methods Eighty SD rats were randomly divid...Objective To investigate effects of electroacupuncture （EA） on expression of intercellular adhesion molecule-1 （ICAM-1） in the rat of local cerebral ischemia-reperfusion. Methods Eighty SD rats were randomly divided into a normal control group, a sham operation group, a model group and an EA treatment group, 20 rats in each group. The thread-obstruction method was used for preparation of ischemia-reperfusion model. Zea-Longa rating criteria were used for evaluation of nervous function disorder; Immunohistochemical SABC method was used for detection of ICAM-1 expression in the microvascular endothelial cell of the ischemic brain region, and ELISA method for the soluble ICAM-1 （slCAM-1） content in peripheral blood. Re. suits After cerebral ischemia-reperfusion, both ICAM-1 expression level in the microvascular endethelium cell of the ischemic brain region and slCAM-1 content in the peripheral blood significantly increased in the model group as compared with the normal group and the sham operation group （P〈0.01）; After EA treatment, the ICAM-1 expression level in the microvascular endothelial cell of the ischemic brain region and slCAM-1 content in the peripheral blood were significantly down-regulated in the EA treatment group as com- pared with the model group （P〈 0.05）. Conclusion After cerebral ischemia-reperfusion, the microvascular endothelial cell of the ischemic brain region releases ICAM-1, which induces inflammatory injury of cerebral tissues; EA treatment can decease the expression of ICAM-1, so as to prevent the brain from the injury.展开更多
AIM： To investigate the correlation between the serum soluble intercellular adhesion molecule-1 （sICAM-1） and the clinicopathologic features and to evaluate the possible prognostic significance of sICAM-1 concentra...AIM： To investigate the correlation between the serum soluble intercellular adhesion molecule-1 （sICAM-1） and the clinicopathologic features and to evaluate the possible prognostic significance of sICAM-1 concentration in colorectal cancer.METHODS： A total of 56 patients （mean age 57.3 years） having transitional cell carcinoma of the colorectal and 25 control patients （mean age 42.6 years） were enrolled in the study. The serum samples of the patients were obtained on the day before surgery. Sera were obtained by centrifugation, and stored at -80℃ until assay. Serum concentrations of ICAM-1 were measured with enzymelinked immunoassay. Differences between the two groups were analyzed by Student＇s t-test.RESULTS： No significant increase of serum slCAM-1 could be demonstrated in the Dukes A1 patients （352.63±61.82μg/L） compared to the control group （345.72±49.81 μg/L,/〉〉0.05）, Dukes A1 patients （352.63±61.82 μg/L）compared to Dukes A2,3 patients （491.17±86.36μg/L,P〈0.05）. Furthermore, the patients with Dukes B had significantly higher serum concentrations of sICAM-1 than those of the control group （496.82±93.04μg/L vs 345.72±49.81μg/L, P〈0.01）. Compared with Dukes A2,3,B colorectal cancer patients, patients with more advanced clinical stage （Dukes C and D） had higher levels of sICAM-1 （743.68±113.74 μg/L vs491.17±86.36μg/L and 496.82±93.04 μg/L, P〈0.001）. The difference was statistically significant in sICAM-1 levels between patients with positive lymph node status and those without lymph node involvement （756.25±125.57μg/L vs 445.62±69.18 μg/L, P〈0.001）.Patients with poorly differentiated colorectal cancer had a higher level of slCAIVl-1 than those with differentiated and highly differentiated cancer （736.49±121.97μg/L vs410.23±67.47 μg/L, P〈0.001）.CONCLUSION： In this study, serum ICAM-1 levels were found to be related to tumor presence, clinical stages,and grade. Increased ICAM-1 in patients with colorectal cancer which should be considered when the diagnostic and/or prognostic usefulness of soluble ICAM-1 is to be evaluated, sICAM-1 should prove useful for monitoring malignant disease stage and for evaluating the effectiveness of various therapeutic approaches for colorectal carcinomas.展开更多
文摘Objective To investigate effects of electroacupuncture （EA） on expression of intercellular adhesion molecule-1 （ICAM-1） in the rat of local cerebral ischemia-reperfusion. Methods Eighty SD rats were randomly divided into a normal control group, a sham operation group, a model group and an EA treatment group, 20 rats in each group. The thread-obstruction method was used for preparation of ischemia-reperfusion model. Zea-Longa rating criteria were used for evaluation of nervous function disorder; Immunohistochemical SABC method was used for detection of ICAM-1 expression in the microvascular endothelial cell of the ischemic brain region, and ELISA method for the soluble ICAM-1 （slCAM-1） content in peripheral blood. Re. suits After cerebral ischemia-reperfusion, both ICAM-1 expression level in the microvascular endethelium cell of the ischemic brain region and slCAM-1 content in the peripheral blood significantly increased in the model group as compared with the normal group and the sham operation group （P〈0.01）; After EA treatment, the ICAM-1 expression level in the microvascular endothelial cell of the ischemic brain region and slCAM-1 content in the peripheral blood were significantly down-regulated in the EA treatment group as com- pared with the model group （P〈 0.05）. Conclusion After cerebral ischemia-reperfusion, the microvascular endothelial cell of the ischemic brain region releases ICAM-1, which induces inflammatory injury of cerebral tissues; EA treatment can decease the expression of ICAM-1, so as to prevent the brain from the injury.
基金Supported by the Youth Science Foundation of Guangdong Medical College, No. 2002110
文摘AIM： To investigate the correlation between the serum soluble intercellular adhesion molecule-1 （sICAM-1） and the clinicopathologic features and to evaluate the possible prognostic significance of sICAM-1 concentration in colorectal cancer.METHODS： A total of 56 patients （mean age 57.3 years） having transitional cell carcinoma of the colorectal and 25 control patients （mean age 42.6 years） were enrolled in the study. The serum samples of the patients were obtained on the day before surgery. Sera were obtained by centrifugation, and stored at -80℃ until assay. Serum concentrations of ICAM-1 were measured with enzymelinked immunoassay. Differences between the two groups were analyzed by Student＇s t-test.RESULTS： No significant increase of serum slCAM-1 could be demonstrated in the Dukes A1 patients （352.63±61.82μg/L） compared to the control group （345.72±49.81 μg/L,/〉〉0.05）, Dukes A1 patients （352.63±61.82 μg/L）compared to Dukes A2,3 patients （491.17±86.36μg/L,P〈0.05）. Furthermore, the patients with Dukes B had significantly higher serum concentrations of sICAM-1 than those of the control group （496.82±93.04μg/L vs 345.72±49.81μg/L, P〈0.01）. Compared with Dukes A2,3,B colorectal cancer patients, patients with more advanced clinical stage （Dukes C and D） had higher levels of sICAM-1 （743.68±113.74 μg/L vs491.17±86.36μg/L and 496.82±93.04 μg/L, P〈0.001）. The difference was statistically significant in sICAM-1 levels between patients with positive lymph node status and those without lymph node involvement （756.25±125.57μg/L vs 445.62±69.18 μg/L, P〈0.001）.Patients with poorly differentiated colorectal cancer had a higher level of slCAIVl-1 than those with differentiated and highly differentiated cancer （736.49±121.97μg/L vs410.23±67.47 μg/L, P〈0.001）.CONCLUSION： In this study, serum ICAM-1 levels were found to be related to tumor presence, clinical stages,and grade. Increased ICAM-1 in patients with colorectal cancer which should be considered when the diagnostic and/or prognostic usefulness of soluble ICAM-1 is to be evaluated, sICAM-1 should prove useful for monitoring malignant disease stage and for evaluating the effectiveness of various therapeutic approaches for colorectal carcinomas.
